Lloyd’s gives in-principle approval for MCI drug testing SIAB
  • X
  • LinkedIn
  • Email
  • Show more sharing options
  • Print
  • X
  • LinkedIn
  • Email
  • Free Trial
  • Log in

Lloyd’s gives in-principle approval for MCI drug testing SIAB

Asta-managed Syndicate 1966 will target £75mn GWP for 2024.

By Rachel Dalton
February 08, 2024
  • X
  • LinkedIn
  • Email
  • Show more sharing options
  • Print
  • X
  • LinkedIn
  • Email
Lloyds building.jpg

Lloyd’s has granted in-principle approval for MCI Syndicate 1966, a syndicate-in-a-box (SIAB) that will offer insurance for clinical trial funding.

The

Subscribers, log in here:

Fuel a smarter strategy with our actionable market intelligence

      • Gain a competitive edge and accelerate decision-making
      • Be empowered by insights that transform confusion to clarity
      • Uncover growth opportunities and prepare for potential threats
      • Fuel a smarter strategy for business growth
Request a free trial Already a subscriber? Log in now

Topics

News Operations/tech Lloyd's Asta
Gift this article